Loading stock data…
$3.45+0.13 (+3.92%)
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions.
Nasus Pharma Ltd. in the Healthcare sector is trading at $3.45 with a market capitalization of $36M. Wall Street consensus targets $19.67 (3 analysts), implying a +470.0% move over the next 12 months. The stock is currently near its 52-week low of $1.98, remaining 35.6% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. Risk note: RSI 70 is overbought against a weak tape. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 |
|---|---|---|---|---|
| Total Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Operating Income | — | — | — | — |
| Net Income | — | — | — | — |
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public...